Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3 randomized, multi-center, double-blind, placebo-controlled study
is to evaluate the efficacy and safety of ACTIMMUNE® (interferon-γ 1b) in the treatment of
Friedreich's Ataxia (FA) and to evaluate the pharmacokinetic (PK) characteristics of
ACTIMMUNE® in FA patients.